Genetic insights into urinary incontinence reveal key tissues, pathways and causal factors

Elisa Moreno[1], Nikhil Arora[1,2], Emily Bertucci-Richter[3], Reyhane Eghtedarian[4], Aristomo Andries[1], Laurent F. Thomas[1,5,6,7], Julie Horn[8,9], Signe N. Stafne[5,10], Sweta Pathak[1], FinnGen, Snehal Patil[3], Dagny Gulla[11], Hanna M. Ollila[4,12,13,14], David M. Evans[15,16,17], Giulia M. Ippolito[18], Wei Zhou[19,20,21,22], Eivind Coward[1], Kristian Hveem[1,23], Ida Surakka[24], Marta R. Moksnes[1,8,25], Brooke N. Wolford[1], Ben M. Brumpton[1,23,26]

1 HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway

2 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

3 Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI 48103, USA

4 Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland

5 Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

6 BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway

7 Clinic of Laboratory Medicine, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

8 HUNT Research Centre, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway

9 Department of Obstetrics and Gynecology, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

10 Clinic of Rehabilitation, St.Olavs Hospital, Trondheim University Hospital, Trondheim, Norway

11 Nordlandet legesenter, Kristiansund, Norway

12 Broad Institute of Harvard and MIT; Cambridge, MA, USA

13 Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital; Boston, MA, USA

14 Centre for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School; Boston, MA, USA

15 Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia

16 MRC Integrative Epidemiology Unit at the University of Bristol, UK

17 University of Queensland Frazer Institute, University of Queensland, Woolloongabba, Australia

18 Department of Urology, University of Michigan, Ann Arbor, Michigan

19 Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

20 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA

21 Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

22 Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

23 HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Levanger, Norway

24 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, US

25 Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway

26 Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim 7030, Norway

Abstract

Urinary incontinence (UI) markedly reduces quality of life, and its genetic basis remains to be elucidated. Here, we performed GWAS meta-analyses of four UI phenotypes, using hospital-based data from 1,045,436 individuals from the Trøndelag Health Study (HUNT), UK Biobank, FinnGen, and the Michigan Genomics Initiative, and self-reported UI from 56,957 females from HUNT and the Nurses' Health Study.

We identified 54 (52 novels) genetic loci associated with at least one UI phenotype. Analyses revealed tissue-specific involvement, with connective and muscular tissues for stress UI, and neural tissues for urge UI, and supported key roles of SUI-prioritized genes in the extracellular matrix organization and muscle function. Further, genetic variations contributes to UI through inflammation, immune, and aging pathways. We identified smoking, higher BMI, higher parity, and pelvic organ prolapse as causal risk factors for UI in females, and benign prostatic hyperplasia in males. Our findings identify key genetic factors, tissues, pathways, and causal underlying UI.

Introduction

Urinary incontinence (UI) is the involuntary leakage of urine and is strongly associated with poor quality of life (1). Most population studies report UI prevalence ranging from 25-45% in adult women (considering occasional leakage) and 1%-39% in males, with prevalences increasing with age (2). However, its burden tends to be underestimated at the population level due to stigma and lack of recognition as a medical condition (3). Two main subtypes of UI are 1) stress urinary incontinence (SUI) defined as urine leakage upon coughing, sneezing, laughing or during physical exertion and 2) urge urinary incontinence (UUI) defined as a urine leakage associated with a sudden need to void that is difficult to defer (4,5). Both subtypes can co-exist, in which case the condition is referred to as mixed urinary incontinence (MUI). Symptoms can be ameliorated by treatment and diverse clinical trials are ongoing (3).

Urinary continence is regulated and maintained through a complex coordination of smooth and skeletal muscles, nerves, bladder mucosa, connective tissues, the pelvic floor, and both the central and peripheral nervous systems (3,6). SUI primarily occurs when bladder

pressure exceeds urethral pressure, often from increased intra-abdominal pressure, insufficient urethral support or sphincter dysfunction (3). In contrast, UUI is mainly characterized by detrusor muscle overactivity, with proposed mechanisms including muscle hyperexcitability, denervation, poor detrusor compliance and bladder hypersensitivity (3). However, UI etiology is far from fully understood. Despite heritability estimates of 39-63% from twin studies for SUI and 42-51% for UUI (7), genome-wide association studies (GWASs) have only identified 12 loci at the genome-wide significance threshold (p-value < 5×10^{-8}) (8–10) and replicated two (9). In addition, the six GWASs of UI are limited by small sample sizes (n=1,507 to 25,685), few results replicated, and only one GWAS included males (8–13). Additionally, these studies did not include downstream analyses such as phenome-wide association studies (PheWASs) to explore pleiotropy and comorbidities, and Mendelian randomization (MR) analyses to assess causal risk factors and guide prevention. Observational studies suggest smoking status (14) and body mass index (BMI) (15,16) as common risk factors for UI, in addition to parity (14,17) and pelvic organ prolapse (PoP) for females, and benign prostatic hyperplasia (BPH) for males (15). However, it is unclear the extent to which these observational associations represent causal effects of the risk factors or the influence of confounding variables.

Here, we performed GWAS meta-analyses of four UI phenotypes (any type of UI (AUI), SUI, UUI and MUI) first using International Classification of Diseases (ICD) codes in up to 1,045,494 individuals from the Trøndelag Health Study (HUNT), UK Biobank, FinnGen and the Michigan Genomic Initiative (MGI), and secondly using self-reported data from up to 56,957 females participants in HUNT and the Nurses' Health Study (NHS). Due to potential sex differences in pathological mechanisms, we also conducted sex-specific analyses. We performed PheWAS using summary statistics from UK Biobank, and calculated genetic correlations between UI and other publicly available phenotypes. Furthermore, we created a polygenic risk score (PRS) and assessed the variance explained in HUNT. Finally, we performed MR to test the causal effect of six suggested risk factors on UI. Identifying novel UI loci, validating previous findings and conducting additional downstream analyses can unravel biological pathways underlying the conditions, suggest drug targets for clinical trials and potentially improve prevention.

Results

GWAS genetic discovery

We performed GWAS meta-analyses of ICD code-based definitions (UI-ICD: AUI-ICD, SUI-ICD, UUI-ICD, MUI-ICD) across four population-based cohorts linked with hospital-based data, encompassing up to 1,045,436 individuals (58,918 cases, 986,518 controls) (**Figure 1; Supplementary Table 1; Supplementary Table 2**) and GWAS meta-analyses of self-reported questionnaire (UI-srq: AUI-srq, SUI-srq, UUI-srq, MUI-srq) including up to 56,957 females (23,392 cases, 33,565 controls) (**Supplementary Table 1; Supplementary Table 3**). The inflation factor (λ) at MAF>0.01 ranged between 0.987 and 1.13 (**Supplementary Table 4**), and the linkage disequilibrium score (LDSC) regression intercepts were below 1 (**Supplementary Table 5**), indicating well-controlled genomic inflation. Using the UI-ICD definitions, the liability-scale single nucleotide polymorphism (SNP) heritability, estimated using LDSC regression, ranged between 7.26% (UUI) and 11.85% (SUI) in females (assuming population prevalences of 5.36% and 4.40%, respectively) and between 2.88% (AUI) and 12.37% (MUI) in males (given population prevalences of 2.56% and 0.08%, respectively (**Supplementary Table 5; Supplementary Table 6**). Using UI-srq definitions, heritability was of 16.55% for SUI and of 14.16% (given a population prevalence of 29.86% and 27.85%, respectively (**Supplementary Table 5; Supplementary Text**)).

The meta-analyses identified 54 independent significant loci (p-value < 5×10^{-8}) associated with at least one UI phenotype, among 52 were novel (**Table 1; Supplementary Table 7-9; Supplementary Figure 1; Supplementary Figure 2**). We replicated two loci previously associated with SUI-srq in females, rs2270016 in our study in *INO80B:WBP1* (rs7607995[(8)]) and rs1448813496 near *MARCO* (rs138724718[(9)]). In total, 49 loci were exclusively found for UI-ICD definitions and four for UI-srq; the locus in *PCOLCE2* was highlighted on both. For UI-ICD definitions, we identified 37 loci in females and eight in males (**Figure 2**). No loci identified in males overlapped with those found in females or in sex-combined analyses. At each locus, the top lead variant had consistent direction across all studies, except for rs1155027 in AUI-ICD females.

To test the robustness of our results, we performed sensitivity analyses using different ICD codes combinations and accounting for potential UI risk factors (**Supplementary text; Supplementary Table 10-13**). The beta estimates for the top lead variants obtained for AUI-ICD and UUI-ICD using alternative definitions showed consistent direction with those obtained in the main analyses (**Supplementary Table 12**). After adjustment with sex-specific risk factors of UI-ICD definitions in HUNT, beta estimates had consistent direction with those obtained in the main analyses (**Supplementary Table 13**).

Protein-altering variants in meta-analysis loci

We identified one protein-altering top lead variant (rs138213197, non-synonymous variant in *HOXB13*) associated with AUI-ICD and SUI-ICD in males (**Supplementary Table 7**). In addition, three top lead variants were in high linkage disequilibrium (LD) (correlation $r^2 > 0.80$) with 25 protein-altering variants: 1) rs2814985 (AUI-ICD in females) with one non-synonymous variant in *UHRF1BP1*, 2) rs9468 (MUI-ICD in females) with a stop-gain variant in *MAPT* and with 18 non-synonymous variants in *MAPT, CRHR1*, *SPPL2C, STH, KANSL1* and *LRRC37A2,* and 3) rs2270016 (SUI-srq) with five non-synonymous variants located in *MOGS*, *MRPL53, TTC31* and *LBX2*. The protein-altering variants mapped to genes associated with diverse traits in the GWAS catalog, spanning many biological areas (**Supplementary Table 14**).

Prioritization of genes, pathways and tissues

To identify tissues involved in UI, we used MAGMA tissue specificity analysis to test associations between tissue specific gene expression profiles and UI-genes (identified by the MAGMA gene-based analysis). Here, we identified 11 tissues (from the Genotype-Tissue Expression [GTEx] Project version 8) in which genes with strong GWAS associations were significantly overexpressed (p-value $< 9.43\times10^{-4}$, Bonferroni correction for 53 tissue types tested) (**Supplementary Table 15**). For females, we identified uterus, tibial artery, sigmoid colon, cervix endocervix and esophagus gastroesophageal junction tissues for SUI-ICD, and cerebellar hemisphere, cerebellum, frontal cortex, hippocampus and anterior cingulate cortex tissues for UUI-ICD. In sex-combined analyses, we identified cortex and hypothalamus for UUI-ICD, in addition to the brain tissues identified in the female-specific analyses. No tissues were

identified for males or for UI-srq definitions. We found seven significantly enriched gene ontology (GO) biological processes through the MAGMA gene-set analysis (p-value < 2.94×10^{-6}, Bonferroni correction for the 17,023 curated gene sets and GO terms tested) (**Supplementary Table 16**).

Cell-type analysis

To identify cell types that may play a role in SUI and UUI subtypes, we used FUMA cell type analysis to test associations between cell specific gene expression profiles and SUI/UUI-genes (identified by the MAGMA gene-based analysis). Prior to the analysis, we selected relevant cell-type datasets: bladder and muscle cell-type datasets for SUI, and hippocampus, frontal cortex and cerebellum cell-type datasets for UUI. We identified skeletal muscle satellites (from limb muscle in mouse) as the only cell type significant for SUI across all single cell RNA sequencing datasets included (p-value < 2.53×10^{-4}, Bonferroni correction for the 149 cell types across all the datasets) (**Supplementary Table 17**). At dataset-level, stromal, smooth muscle and leukocyte cell types were associated with the SUI-genes in bladder tissues, additionally to mural cell type (from abdomen skeletal muscle) and tendon cell type (from pelvic diaphragm skeletal muscle). For UUI, no significant enrichment was found across all datasets (p-value < 4.31×10^{-5}, Bonferroni correction for the 1159 cell types across all the datasets). However, we observed dataset-level enrichment for neurons in the hippocampus and for neuroblast in the cerebellum (uniquely in the dataset with first trimester of developmental cells).

Colocalization

To identify shared causal variants for UI and the expression of genes nearby, and therefore strengthen the identification of candidate genes, we performed Bayesian colocalization analyses of 13 unique GWAS loci for UI and cis-expression quantitative trait loci (cis-eQTLs) in relevant tissues (**Supplementary Table 18**). We found strong evidence (posterior probability for shared causal variant (PP4) > 75%) for a shared causal variant (colocalization) of GWAS loci for UI-ICD definitions in females and eQTLs for *HSPA4* (muscle), *MET* (tibial artery, esophagus muscularis, sigmoid colon), *DEPTOR* (brain spinal cord, esophagus mucosa, sigmoid colon), *CHRDL2* (putamen), *PCOLCE2* (fibroblast), *NCAM1* (tibial artery). For males we found *PTK2*

(several brain tissues) and for sex-combined *EEFSEC* (tibial nerve). We also identified strong evidence for colocalization of GWAS loci for UI-srq in females and eQTLs for *STAM2* (muscle). Colocalization in bladder was weak using ±500 kb around the lead variant but increased markedly when restricted to a conservative ±50 kb window and the PP4 was close from 75%, suggesting the shared signal is localized near the lead variant for *LRRC37A*, *LRRC37A*2 and *KANSL1-AS1*.

Genetic correlation of UI phenotypes

To quantify the extent of shared heritable influences between SUI and UUI subtypes, we used LDSC regression and estimated pair-wise genetic correlations (r_g) of 0.86 in females (p-value= 5.70×10^{-166}) and 0.58 in males (p=3.60×10^{-3}) using UI-ICD definitions, and of 0.60 in females (p-value= 3.80×10^{-32}) using UI-srq (**Supplementary table 19**). The pair-wise genetic correlations for SUI-ICD between females and males was of 0.17 (p-value=0.1275), and of 0.44 for UUI-ICD between females and males (p-value=$7.56\text{x}10^{-6}$).

We also conducted pair-wise genetic correlations of UI-ICD definitions with 2,871 phenotypes from different studies publicly available (18). This revealed up to 644 phenotypes with significant genetic overlaps with the four UI types in females and 25 in males (p-value < 1.74×10^{-5}, Bonferroni correction for the 2,871 phenotypes) (**Supplementary Table 20; Supplementary Figure 3**). After excluding phenotypes using ICD codes related to UI or bladder disorders and for females, SUI was most strongly genetically correlated with genital prolapse (r_g=0.58, p-value=1.20×10^{-19}), UUI with weight gain in worst depression episode (r_g=0.65, p-value=2.42×10^{-8}) and MUI with reason of smoking cessation due to illness or ill health (r_g=0.64, p-value=1.36×10^{-5}). UI subtypes were also positively correlated ($r_g > 0.3$) with muscle related disorders, joint diseases, digestive related disorders, skin and subcutaneous diseases (for UUI only), circulatory system diseases (for UUI and MUI) and teeth related disorders (higher genetic correlations with UUI and MUI subtypes than with SUI). Female reproductive traits showed negative correlation with SUI and UUI. In males, UUI was most strongly correlated with hyperplasia of prostate ($r_g = 0.78$, p-value=1.80×10^{-13}) and positive correlations ($r_g > 0.29$) were found also with urine retention and prostate cancer. For both sexes, UUI was positively correlated with frequency of urination and polyuria, and urinary tract infection (UTI).

Phenome-wide associations studies

To investigate potential pleiotropy of the top lead variants for UI with other phenotypes, we performed PheWAS using 1523 publicly available phenotypes (biomarkers, phecodes and continuous traits) from the UK Biobank. We identified 61 UI-variants as significantly associated (p-value < 4.50×10^{-7}, Bonferroni correction for 1523 phenotypes and 73 variants) with at least one trait in UK Biobank (**Supplementary Table 21-23, Supplementary Figure 4**). For females, we identified 18 biomarkers, 19 phecodes and 157 continuous traits associated with 26 variants. Most notably, these associations spanned the genitourinary system (mainly prolapses), the circulatory system, kidney function, metabolic traits (BMI, LDL- and HDL-cholesterol), reproductive traits (age at hysterectomy, lifetime number of sexual partners, age at first sexual intercourse, age at menarche, birth weight of first child), chronic pain, socio-economic status, smoking status and alcohol consumption. For males, we identified three biomarkers, five phecodes and 15 continuous traits associated with four variants, mainly prostate related traits (prostate cancer, hyperplasia), diabetes, kidney function, BMI related traits, circulatory system and chronic pain.

UI drugs and gene target

We queried DrugBank to determine whether genes identified in our study are known targets of existing drugs for UI. Among the 13 drugs identified in DrugBank (one for SUI and 12 for UUI or overactive bladder syndrome), none were targeting a protein that is coded by a gene we identified through our meta-analysis (**Supplementary table 24**).

Polygenic risk scores for urinary incontinence

To evaluate the potential predictive effect of PRSs in UI, we constructed PRSs using pruning and thresholding (P+T) and PRS-CS (continuous shrinkage) methods and GWAS meta-analysis summary statistics from UI-ICD definitions. The PRS explained up to 2.0% of the variation in UI in females (SUI, PRS from PRS-CS). The variance explained for males was 0.2% (SUI, PRS from PRS-CS) (**Supplementary Table 25, Supplementary Table 26**). Using PRS-CS, the prevalence in the first decile was 5.45% for SUI and 5.60% for UUI compared to 15.49% and 11.38%, respectively, in the tenth decile (**Supplementary Figure 5**). In females, one standard

deviation (SD) increase of the PRS was associated with an increased SUI risk of 23% (P+T) and 40% (PRS-CS), while in males it was of 7% (P+T) and 16% (PRS-CS).

Mendelian Randomization

We performed two-sample MR to investigate the causal effect of six risk factors on UI: smoking status, BMI, alcohol consumption and specifically for females, PoP and parity, and for males, BPH. In the sex-combined analysis we found evidence of a positive effect of smoking status and BMI on UI. We estimated an increased risk for UI in smokers compared to non-smokers (increased risk of 7-19% depending on UI phenotype) and per SD increase in BMI (14-36%), with consistent direction across UI phenotypes (**Supplementary Table 27**). For females, we found strong evidence for a causal effect of higher parity and PoP on UI. We estimated an increased risk for UI for each additional child ever born (82-128%) and among women experiencing PoP (12-24%), with consistent direction across UI phenotypes. For males, we found strong evidence of a causal effect of BPH on UI (2-34%), with effect size estimates consistent direction across UI phenotypes. However, the analyses for alcohol consumption showed less consistent results across UI phenotypes. Estimates from sensitivity analyses generally aligned with the inverse-variance weighted (IVW) results, although MR-Egger showed some attenuation for smoking status and BMI. Sex-stratified analyses results were consistent with sex-combined analysis results for females but not for males (IVW results) and, MR-Egger intercepts for BMI in females were close to 1 (p-value < 0.5) (**Supplementary Table 28**). Using Steiger filtering, rs4944936 explained more variance in AUI and SUI than in PoP. However, estimates remained in the same direction after excluding this SNP (**Supplementary Table 29**). All instruments had an F-statistic >10, indicating sufficient strength to minimize weak instrument bias. The genetic instruments explained between 0.2% (parity) and 5.8% (BPH) of the variance in the exposures (**Supplementary Table 30**). Except smoking status in males, all exposures showed instrument heterogeneity (Q-statistic test p-value < 0.05).

Discussion

We performed the largest GWAS meta-analysis of UI to date and identified 54 genetic loci (52 novel) associated with at least one UI type. This replicated two previously identified loci

293 (*INO80B:WBP1; MARCO*) for SUI in females. Analyses revealed tissue-specific involvement for
294 subtypes of UI, with enrichment of SUI-associated genes in muscle and connective tissues,
295 and enrichment of UUI-associated genes in neural tissues. These results were supported by
296 key roles of SUI-prioritized genes in the extracellular matrix (ECM) structure (*PCOLCE2* and
297 *NCAM1*) and proper muscle function (*HSPA4* and *DEPTOR*). Findings from the PheWAS and
298 genetic correlation analyses aligned with each other, supporting the involvement of genetics
299 in UI pathology through diverse tissue structures including connective tissues, and pathways
300 including inflammation, immune system, and aging. Further, we confirmed the causal effects
301 of smoking status, higher BMI, higher parity, PoP on UI in females and BPH on UI in males.

302 We replicated two loci out of the 12 previously reported (p-value<5×10^{-8}) (8–10). The
303 *INO80B:WBP1* locus was previously associated with SUI in models adjusting for BMI, parity,
304 and diabetes, whereas we identified it in our main analysis (models non-adjusted for clinical
305 factors) (8). Among the six GWAS of UI previously published, only three reported loci at the
306 genome-wide significance threshold of p-value<5×10^{-8}. This could be explained by 1)
307 heterogeneous phenotype definitions from self-reported questionnaires and ICD codes, which
308 may not be comparable, 2) a focus of females-specific GWAS and, 3) the limited sample size
309 (n<26,000) of previous studies. We did not replicate genes from candidate gene studies (7,19).

310 We identified three top lead variants in high LD with protein-altering variants: 1)
311 rs2814985/rs9469860 were mapped to *UHRF1BP1* and *SNRPC*. Individuals with mixed
312 connective tissue disease frequently produce autoantibodies against a protein encoded by
313 *SNRPC* (20). Given that connective tissue integrity is essential for bladder support, its
314 dysfunction may contribute to UI. 2) rs9468 was in high LD with protein-altering variants in
315 genes involved in tauopathy, dementia and Alzheimer's disease (*MAPT* and *STH)*. 3) rs2270016
316 was in high LD with a protein-altering variant in *LBX2, MOGS, MRPL53;* these genes have been
317 suggested to influence SUI with unclear described roles (13). As replicated in our PheWAS, the
318 protein-altering variant rs138213197 in *HOXB13* is known to be associated with prostate
319 cancer (21,22); a likely comorbidity causing UI.

320 In females, our findings suggest sex-specific tissues to be involved in UI subtypes:
321 smooth muscles, connective tissues and mucosa tissues for SUI, and brain related tissues for
322 UUI. Smooth muscle constitutes the detrusor muscle of the bladder, allowing the bladder to
323 relax during filling phase and to contract during the voiding phase. The smooth muscles also
324 constitute urethral sphincter which regulates its opening to prevent urine leakage. This is done

325 in coordination with connective tissues and pelvic floor muscles. Connective tissues maintain
326 the structural integrity of organs and, in the context of urinary continence, provide structural
327 support to the urethra and bladder through the ECM. Within the ECM, fibroblasts produce
328 collagen and other structural proteins, providing tissue elasticity and strength and the bladder
329 mucosa is composed of ECM. Disruption of any of these components may contribute to UI.

330 These findings are supported by the role of the SUI-prioritized genes in the ECM
331 (colocalization in fibroblasts and tibial arteries, a tissue composed of connective tissues)):
332 *PCOLCE2* by playing a role in collagen formation (23,24) and *NCAM1* by encoding a cell surface
333 glycoprotein that mediates cell-cell and cell-ECM matrix interactions (25,26). Secondly, SUI-
334 prioritized genes are known to play a role in muscle cell structure, support and contraction:
335 *HSPA4* (colocalization in muscles) is known to support protein cellular homeostasis
336 maintenance and was upregulated during muscle regeneration (27), while *DEPTOR*
337 (colocalization in gastrointestinal tissues) regulates myocyte protein metabolism, and its
338 reduced expression can improve muscle atrophy (28). Thirdly, smooth muscle cells, satellite
339 cells, and tendon cells were cell types associated with SUI-genes. While the smooth muscle
340 cells form the detrusor muscle and enable the bladder to relax (filling phase) and to contract
341 (voiding phase) (29), the satellite cells contribute to tissue regeneration (30) and the tendon
342 cells form the tendinous arch, a dense fibrous connective tissue anchoring muscles to the
343 pelvic bone, supporting continence (3,31).

344 The findings for UUI tissues in females are firstly supported by the role in neurological
345 disorders of UUI-prioritized genes, that suggest neural pathways*: PTK2* (colocalization in
346 diverse brain tissues) has been associated with tau-induced neurotoxicity regulation in
347 neurodegenerative diseases and *EEFSEC* (colocalization in tibial nerve) with
348 neurodevelopmental disorders with progressive neurodegeneration. Although these findings
349 could suggest potential comorbidities, the absence of associations with neurodegenerative
350 diseases in genetic correlations and PheWAS analyses reinforces that the prioritization of
351 these genes may not be due to such comorbidities. Secondly, brain tissues involvement may
352 reflect neurogenic detrusor overactivity and can lead to UUI due to a disrupted bladder-
353 central nervous system coordination after surgery, injury or disease. Our findings align with
354 neuromodulation, current therapies for UUI which target bladder, nerves, brain signaling
355 pathways. The main enrichment analysis included the *NFIA* locus*,* previously associated with
356 UI (32); however excluding this locus yielded similar tissue associations, thereby indicating

357 that brain enrichment was not only driven by this locus. Thirdly, the cell-type analysis
358 identified neuroblast cells from the cerebellum and neurons from the hippocampus
359 associated with UUI-genes. The cerebellum coordinate the detrusor contraction, control the
360 pelvic floor in the micturition reflex and activate during the filling phase (33,34).

361 The findings from the genetic correlations and the PheWAS aligned with each other,
362 supporting the involvement of genetics in UI through ECM and connective tissues structures.
363 In females, we found genetic correlations of UI with ECM-related and connective-related
364 disorders such as PoP, chronic periodontitis, osteoarthritis (involve ECM but not connective
365 tissues) and myositis. Similarly, seven of nine prolapse-associated SNPs had same directions
366 with UI, and rs9306894-G was associated with esophagus disorders, suggesting the
367 involvement of connective tissues. We also observed the association of rs9468-C with UI and
368 osteoarthrosis with concordant effect directions. Additionally, the genetic correlations of PoP
369 with UI could reflect the involvement of smooth muscles and the correlation of
370 musculoskeletal disorders (e.g. myalgia, myositis and muscle weakness) with UI could reflect
371 the involvement of skeletal tissues. Our findings also support the involvement of genetics in
372 UI through several pathways, mainly those related to inflammation and immune system. We
373 found correlations of UI with many inflammatory conditions such as gingival and periodontal
374 diseases, chronic periodontitis and rheumatoid arthritis. Our findings suggest that the
375 previous reported association between overactive bladder and tooth loss due to chronic
376 periodontitis (35) may be driven by shared genetic factors, indicating common shared
377 biological pathways. We also highlighted moderate correlations between UTI and UUI. Finally,
378 the association of rs9468-C with UI and osteoarthrosis supports an age-related pathway, given
379 that osteoarthrosis has a higher prevalence in older adults.

380 Current pharmacotherapeutics for UI target subtype-specific mechanisms which align
381 with our findings, particularly for UUI. Medications for UUI target neural signaling by acting as
382 antagonists of muscarinic receptors or β3-adrenergic receptor agonists. Antagonists of
383 muscarinic receptors reduce parasympathetic cholinergic activity and therefore involuntary
384 detrusor contractions, while β3-adrenergic receptor agonists enhance sympathetic signaling
385 and promote smooth muscle detrusor relaxation during the filling phase to reduce urgency. In
386 contrast, the only listed medication for SUI in the DrugBank (Duloxetine) acts by enhancing
387 urethral sphincter contraction via central and peripheral neural mechanisms. While this
388 improves functional sphincter deficit observed during intra-abdominal pressure, it does not

389 directly target urethral muscle structure, connective tissues or ECM, which our analyses
390 identified as central in SUI pathophysiology. Further, none of the approved drugs target
391 proteins encoded by genes identified in our meta-analysis, highlighting a potential for
392 genetically informed therapeutic development and repurposing.

393 Despite the convincing roles of the associated genes in UI pathology, the PRSs we
394 constructed had limited predictive power. Given the range of PheWAS traits identified, other
395 clinical comorbidities may serve as stronger predictors for UI risk.

396 Two-sample MR confirmed the causal effect of smoking status, higher BMI, higher
397 parity, PoP and BPH on UI, aligning with previous observational studies (14–17). Sex-specific
398 analysis suggested that smoking status and BMI were clear risk factors for UI in females but
399 not in males. Our results for alcohol consumption were not consistent across all phenotypes.
400 However, we observed a protective effect on UUI in males, as previously reported in an
401 observational study including men (36). Through MR we highlighted causal associations
402 between parity and UI, and through PheWAS we find genetic variation for UI to also be
403 associated with birth weight of the first child. These findings highlight that childbirth is a
404 critical period for women to develop UI and reinforces the importance of raising awareness to
405 empower women to recognize symptoms, report them without stigma and seek appropriate
406 care. It also emphasizes the need for clinicians to proactively initiate discussions about UI pre-
407 and post-partum and manage the symptoms accordingly.

408 This study had several advantages and clear limitations. To date, this is the largest
409 meta-analysis of ICD code-based definitions (>1M individuals) of UI and of self-reported UI
410 (>56,000 individuals). The large sample size, and consistent effect directions support the
411 generalization of our findings. However, the study was limited to individuals of European
412 ancestry. Future replication in populations with diverse genetic ancestries is needed. UI is a
413 broad term encompassing multiple ICD codes. Due to country-specific usage of the ICD code
414 system, we collaborated with clinicians in Norway and the US to define the phenotypes
415 variables. Because ICD codes may only capture severe cases of UI or patients with
416 comorbidities; we also used self-reported data to identify moderate cases. Given these
417 differences, we estimated the genetic correlation between self-reported and ICD code-based
418 definitions and analyzed them separately. Population-based self-reported data was used to
419 represent the general population while hospital-based data increased sample size and variant
420 detection. However, this may have introduced selection bias, as hospital participants are more

likely to present with severe UI, comorbidities or potentially have higher health literacy promoting health-seeking behavior. Further, our sensitivity analyses using all World Health Organization ICD codes for UUI and AUI definitions, and adjusted for potential confounders, did not show material differences to our main analyses, supporting the robustness of our results. Finally, no overlapping loci were found between sexes, suggesting distinct genetics for UI. However, this could result from limited sample size and lower prevalence in males. This was supported by the female-derived PRSs being associated with an increase of UI in males (**Supplementary Table 25; Supplementary Table 26**).

In conclusion, our study increased the number of loci associated with UI through the largest GWAS meta-analyses of hospital-based and self-reported data to date. We identified sex- and subtype- specific genetic mechanisms underlying UI and highlighted tissue-specific involvement in the two main subtypes of UI. We confirmed the causal effect of smoking, higher BMI, parity and PoP on UI in females and BPH on UI in males. Our findings enhance our understanding of UI genetics, underlying tissues, and causal factors. Finally, these results highlight the need of genetically informed therapeutic development and repurposing.

Methods

Cohort descriptions

HUNT

The Trøndelag Health Study (HUNT) is a large Norwegian longitudinal population-based study (37–39). Self-reported data, clinical measurements and biological samples have been collected over forty years: HUNT1 [1984-1986], HUNT2 [1995-1997], HUNT3 [2006-2008] and HUNT4 [2017-2019]. In total, ~229,000 adults (≥20 years) have participated in at least one HUNT study and ~88,000 have been genotyped (40). Participants were linked to electronic health records allowing for a longitudinal follow-up using ICD codes available at the local hospitals starting from 1987. Sample and genetic variant quality control (QC) have been reported elsewhere (40).

UK Biobank

The UK Biobank is a population-based database gathering self-reported health information, clinical measurements and biological samples for ~500,000 adults living in the UK (aged 40-69 years) (41). At baseline, participants consented to link their data to electronic health-related

451 records (National statistics, hospital information and primary care data) for follow-up. In total,
452 488,377 participants were genotyped (41).

453 FinnGen

454 FinnGen is a Finnish public-private collaborative study combining data from digital health
455 record from Finnish health registries with genotyping data (42). The data freeze 12 includes
456 520,210 participants. Sample and genetic variant QC are described elsewhere (42,43).

457 MGI

458 The MGI is a biobank including patients receiving care at the Michigan Medicine medical
459 center from 2012 onwards. Approximately 95,000 participants (aged ≥ 18 years) consented to
460 link their genetic data to their electronic health records (44); therefore, in the Data Freeze 6 >
461 80,000 participants had genotyping data. Sample and genetic variant QC are described
462 elsewhere (44).

463 NHS

464 The NHS cohort was initiated in 1976 and included >121,700 nurses (aged 30-55 years) in the
465 NHSI. Participants answered biennial questionnaires about their health and lifestyle and
466 provided blood and cheek cell samples (45). Similarly, the NHSII recruited 116,430 additional
467 nurses (aged 25-42 years in 1989). Sample and genetic variant QC are described elsewhere
468 (8,46). We used summary statistics from Penney and al. 2019 using NHS data and publicly
469 available in the GWAS Catalog (8).

470 For each cohort, the details of the genome-wide genotyping, imputation and quality control
471 methods are provided in (**Supplementary Table 31**).

472

473 Phenotype definitions

474 Self-reported phenotype definition

475 *HUNT*

476 Answers about UI were collected in the baseline questionnaires in HUNT 2-4. The questions
477 differed between the self-reported questionnaire, sexes and age (**Supplementary Table 32**).
478 We combined the questions from the HUNT self-reported and constructed four phenotype
479 definitions: any type of UI (AUI-srq), SUI (SUI-srq), UUI (UUI-srq) and MUI (MUI-srq)

480 (Phenotype definitions and number of individuals included are presented in **Supplementary**
481 **Text; Supplementary Table 3**).

482 *NHS*

483 Four definitions have previously been used: SUI, UUI, MUI and all UI. In brief, UI cases reported
484 at least weekly UI at most questionnaires (≥4 from the 7 questionnaires in NHSI, ≥3 from the
485 five questionnaires in NHSII). Definitions are reported elsewhere (8) and the number of
486 individuals included in our analysis is presented in **Supplementary Table 3**.

487 ICD-code based phenotype definitions

488 We constructed four ICD code-based UI definitions: any UI (AUI-ICD), SUI (SUI-ICD), UUI (UUI-
489 ICD) and MUI (MUI-ICD) by combining ICD Ninth Revision (ICD-9) and tenth Revision (ICD-10)
490 codes. We used definitions from the WHO dictionary for ICD-10 (version 2019;
491 https://icd.who.int/browse10/2019/en#) for HUNT, UK Biobank and FinnGen and ICD-10-CM
492 for MGI from the National Center for Health Statistics (version October 1st, 2023;
493 https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2024/). The
494 phenotype definitions were constructed in collaboration with local physicians to ensure that
495 they correctly represented the coding systems used in Norway and in the US (**Supplementary**
496 **Table 33, Supplementary Text**). The number included for each definition are presented
497 **Supplementary Table 2**.

498

499 Genome-wide association analyses

500 We performed GWAS using a generalized mixed model as implemented in SAIGE (47) version
501 1.03 for GWAS using HUNT data and version 0.35.8.3 for GWAS using UK Biobank data. We
502 adjusted the analyses for age, sex, the first ten genetic principal components (PCs) and
503 genotyping batch. We excluded variants with minor allele count (MAC) < 10 or imputation
504 INFO score < 0.3. We inspected QQ plots, estimated the genomic inflation factor (lambda) and
505 intercepts using LD score regression (48,49).

506

507 Meta-analyses

508 We used METAL to conduct 16 fixed-effect inverse variance weighted GWAS meta-analyses of
509 the effect size estimates and standard errors of 1) the HUNT questionnaire-based and NHS

510 summary statistics including up to 56,957 individuals of European ancestry (50) and 2) ICD
511 code-based definitions from HUNT, UKBB, FinnGen and MGI including up to 1,045,436
512 individuals of European ancestry. Prior to the meta-analysis, we converted the genomic
513 positions in HUNT and UKBB from GRCh37 to GRCh38 using LiftOver from UCSC (51). In
514 addition, we applied genomic control correction based on the estimated inflation factor
515 (lambda) for each cohort. Prior to meta-analyses, we assessed the genetic correlations
516 between ICD code-based definitions and self-reported definitions from HUNT; the genetic
517 correlation was low to moderate ($0.53 < r_g < 0.65$) and we decided to treat the phenotype
518 definitions separately (**Supplementary Table 34**). We checked for heterogeneity using the I^2
519 from METAL (acknowledging heterogeneity if p-value < 0.05/(number of top lead SNPs for the
520 phenotype)) (**Supplementary Table 7**). Using the summary statistics from the meta-analyses,
521 we calculated the lambda (minor allele frequency > 0.01) (**Supplementary Table 4**) using all
522 the variants available and estimated the intercept (**Supplementary Table 5**) using the LD Score
523 regression (48,49), restricting to the variants present in the HapMap3 SNP-list.

524 Sensitivity analysis

525 To check whether the identified loci were reflected by known risk factors more than UI, we
526 performed GWAS using HUNT adjusted for known UI risk factors (**Supplementary Text**).
527 Additionally, we performed GWASs using alternative combinations of ICD codes to investigate
528 robustness of main analysis definitions as described in the **Supplementary Text**.
529

530 Genomic risk locus definition

531 We used FUMA v1.6.1-1.6.5 (52) (https://fuma.ctglab.nl/) to annotate and positionally map
532 variants from the meta-analyses after converting genomic positions to build GRCh37 using the
533 UCSC LiftOver (51). This was done because the FUMA versions used did not handle data of
534 build GRCh38. Genomic risk loci were defined by FUMA using default parameters (maximum
535 lead SNP p-value $< 5\times10^{-8}$, r^2 threshold for independent significant SNPs ≥0.6; 2nd r^2 threshold
536 for lead SNPs ≥0.1, maximum distance of LD blocks to merge ≤ 250kb (kilobases)). The SNP
537 with the smallest p-value in each locus is termed 'top lead SNP' in FUMA, a term we kept here
538 for clarity. We used LD correlation coefficients from the 1000G European reference panel (53)
539 and regional plots were generated by FUMA using LocusZoom (54) (**Supplementary Figure 2**).

540 We verified that no variants were excluded due to the filtering on the 1000G reference panel;
541 if a variant was filtered out and was within -/+ 250 kb of the top lead variant identified by
542 FUMA, we considered it in this locus. However, if the variant was outside the -/+ 250 kb range,
543 we considered it a new locus; these results are marked of * in the genomic locus tables (five
544 in total). For the five loci we identified by manual search, we generated the LocusZoom plots
545 for four (variant from the locus with the smallest p-value: rs1448813496, rs765377367,
546 rs10993994 and rs201998020) using the reference panel generated from HUNT2-3
547 (**Supplementary Figure 2**). For rs191824624, we could not generate LocusZoom plot as the
548 variant was not available in HUNT.
549 Overlapping loci between definitions were counted once and considered novel if not
550 previously associated with UI.
551 We conducted the following downstream analyses using the top lead variants/loci identified
552 by FUMA.

553 Gene-based, gene-set and tissue expression analyses

554 We performed MAGMA gene-based, gene-set and tissue expression analyses using FUMA.
555 The genome-wide gene association analysis (gene-based analysis) was performed using
556 MAGMA (v1.6) (55) and all variants located within protein-coding genes from Ensembl. The
557 significance threshold was corrected for the number of protein-coding genes for which the
558 input SNPs were mapped.
559 Further, we used MAGMA to perform gene-set analyses on the genes identified in the gene-
560 based analysis, testing them with 17,023 genes set (Curated gene sets and Gene Ontology
561 terms) from the MSigDB v7.0 database. The gene-set p-values were corrected for the 17,023
562 curated gene sets and GO terms tested (p-value $< 2.94\times10^{-6}$ after Bonferroni correction)
563 To identify expression patterns of the prioritized genes across different tissues we performed
564 MAGMA tissue specificity analysis using gene expression data from 53 specific tissue types in
565 the Genotype Tissue Expression (GTEx) Project v8 (https://www.gtexportal.org/). The genes
566 were prioritized using the results of the gene-based analysis. Tissues were identified as
567 significant if their p-value $< 9.43\times10^{-4}$, Bonferroni correction for the 53 tissue types tested.
568

Cell-type analysis

We used cell-type specificity analysis as implemented in FUMA to identify cell types potentially involved in UI and its subtypes. Details about dataset selection are presented in the **Supplementary Text**.

Colocalization analysis

To test if UI loci may influence gene expression in relevant tissues, thereby suggesting a potential role of these genes in UI, we performed Bayesian colocalization using the R 'coloc' package (56) with summary statistics from the UI GWAS loci and publicly available eQTL data. We used Open Targets Genetics (https://genetics.opentargets.org/) to identify top lead variants with available eQTL data in relevant tissues within a gene mapped by FUMA, and selected these eQTLs and the corresponding GWAS loci for the analyses. Selection of the relevant tissues was done using the results of the MAGMA gene property analysis for tissue specificity and literature (**Supplementary Text**). We retrieved European ancestry eQTL data from the eQTL catalog (57) (GTEx v8, CommonMind, ROSMAP, FUSION and Alasoo 2018) using a publicly available API (function 'request_association_from_api') and adjusting parameters to obtain eQTL -/+ 500kb regions around the variant of interest (https://github.com/eQTL-Catalogue/eQTL-Catalogue-resources/blob/master/tutorials/API_v2/eQTL_API_tutorial.md). When eQTLs evidence for the same tissue but from two different datasets, we prioritized data from the Gtex v8. For some SNPs, eQTL evidence was identified in Open Targets Genetics but was not retrieved through the API. This may be due to the API accesses data from the eQTL Catalogue, whereas the eQTL evidence displayed in Open Targets Genetics may originate from the original datasets. The eQTL Catalogue reprocesses these datasets using standardized pipelines and additional quality control and filtering criteria, which may result in some associations not being included. In cases where the eQTL evidence was not available from eQTL Catalog but Open Targets showed evidence in a GTEx v8 dataset, we retrieved the corresponding data from GTEx v8 and performed colocalization. Overall, we tested 13 of the 14 unique GWAS loci for UI identified by Open Targets Genetics.

We conducted separate analyses for bladder tissue using GTEx v10; bladder tissue was not available in the eQTLCatalog (https://www.gtexportal.org/home/downloads/adult-gtex/qtl).

599 We selected variants with eQTL evidence for the top lead variant of the GWAS in genes
600 prioritized by FUMA (using significant variant-gene associations based on GTEx permutations).
601 We identified one locus (chromosome 17) and considered the locus region and eQTL ±500 kb
602 around the variant of interest. We considered *KANSL1-AS1* (not prioritized by FUMA) which is
603 an antisense transcript of *KANSL1* (prioritized by FUMA). Given that bladder tissue is most
604 relevant to UI, we conducted a sensitivity analysis restricting cis-eQTLs to ±50 kb around the
605 lead variants to focus on local regulatory effects.
606 We set prior probabilities at 10^{-4} for phenotype or gene expression alone, and 10^{-6} for both
607 (58). We considered posterior probabilities (PP4) > 75% as strong evidence of a shared causal
608 variant for UI and gene expression. We used case-control ('cc') when formatting the data from
609 the GWAS in coloc and reported the proportion of cases accordingly ('s').
610

611 ## Heritability and genetic correlation

612 We estimated SNP heritability at the liability scale using LD score regression
613 (https://github.com/bulik/ldsc) (48,49) and estimated sample and population prevalences
614 (**Supplementary Text**). Additionally, we estimated SUI-ICD and UUI-ICD pairwise genetic
615 correlation. We restricted these analyses to SNP from HapMap3 and used LD scores derived
616 from the 1000G European reference panel
617 (https://alkesgroup.broadinstitute.org/LDSCORE/README_new_data_location.txt).
618 Additionally, we estimated genetic correlations between UI ICD code-based phenotypes and
619 2871 traits publicly available from the Complex Traits Genetics Virtual Lab server (18) using LD
620 score regression from European reference panels (48,49). We reported genetically correlated
621 phenotypes (p-value < 1.74×10^{-5}, Bonferroni correction for 2,871 phenotypes). The
622 phenotypes in genetic correlations with UI at r_g> 0.4 were plotted by relevant categories; for
623 clarity, we limited the plot at the 50 largest associations.
624

625 ## Phenome-wide association studies

626 We tested pleiotropic associations of the top lead variants identified in the meta-analyses (70
627 unique variants for ICD code-based definitions and three for self-reported definitions) with
628 1523 outcomes: 1326 'phecodes' (ICD codes groupings representing clinically concepts for

research (59)), 30 biomarkers and 167 continuous traits. We used publicly available GWAS summary statistics of European ancestry individuals (https://pan.ukbb.broadinstitute.org/). Results were considered significant if p-value < 4.50×10^{-7}, Bonferroni correction for the 1523 phenotypes and the 73 variants.

UI drugs and gene target

To prioritize genes identified, we used DRUGBANK (https://go.drugbank.com/) to verify whether drugs currently used for UI (or in clinical trials) targeted the genes identified in our meta-analyze. We searched using the "Indications" option for 'stress urinary incontinence', 'urge urinary incontinence', 'urinary incontinence' and 'mixed urinary incontinence'. We selected the categories reported in the **Supplementary Table 24** in the column Indication (search ID).

PRS

We performed PRS-CS auto (60) for ICD code-based phenotypes leaving out HUNT. We used the UK Biobank European LD reference panel and computed the score using Plink2 (https://github.com/lcstoshio/tutorial_PRSCS_PRSCSx/blob/main/tutorial_PRScs.md and https://github.com/globalbiobankmeta/PRS/blob/main/run_prscsx_pipe.md) (60). We used the P+T method to generate the PRS for phenotypes with minimum five loci identified to avoid non-normality. We ran a meta-analysis excluding HUNT and extracted effect size estimates for each top lead variant. PRSs in HUNT were the sum of the number of risk alleles (from dosage), weighted by its regression coefficient (β) as implemented in Plink2 linear scoring. For both methods, we standardized the score to a normal distribution and estimated the associations between the PRS and UI in HUNT using logistic regression. Further, we estimated the variance explained by the PRS using the difference of Nagelkerke R^2 estimates between a full model (PRS and covariates [age, sex, PCs and genotyping batch]) and a null model (covariates). We plotted UI prevalence by PRS deciles using the PRS-CS results.

Mendelian Randomization

We conducted two-sample MR to investigate the causal effects of six previously reported risk factors for UI: smoking status (14), alcohol consumption (36), BMI (15,16), parity (14,17) and pelvic organ prolapse for females, and benign prostatic hyperplasia for males (15). SNP-exposure association estimates were obtained from GWAS summary statistics of European ancestry populations from publicly available data (17,61–64). For sex-specific analyses and when available, we used sex-specific SNP-exposure association estimates.

Genetic instruments were derived by clumping ($r^2 < 0.001$) the lead SNPs for each risk factor (reported in the tables of the included studies), except for BMI, where we used genome-wide summary statistics and selected independent SNPs ($r^2 < 0.001$) passing the genome-wide significance threshold ($p < 5 \times 10^{-8}$). SNP–outcome associations for the selected genetic instruments were extracted from the GWAS meta-analyses of AUI-ICD, SUI-ICD, UUI-ICD and MUI-ICD. After harmonizing the risk alleles, we performed IVW two-sample MR to estimate associations, reporting odds ratios with 95% confident intervals, F-statistics, R^2, and Cochran's Q for heterogeneity. We performed sensitivity analyses including simple median, weighted median, MR-Egger methods. For binary exposures, estimates were scaled to represent the risk increase in UI per doubling (2-fold increase) in the prevalence of exposure, by multiplying the beta estimates by 0.693 (65). Steiger filtering was applied to verify whether each SNP explained more variance in the exposure than in the outcome; when SNPs explained more variance in UI, we re-ran the IVW MR and sensitivity analyses excluding those instruments.

Statistics and reproducibility

Statistical analysis has been performed using R v.4.2.3-4.5.2 and FUMA v1.6.1-1.6.5. The definitions used are provided in **Supplementary Table 33** for ICD-based definitions and **Supplementary Text** for self-reported definitions. The descriptive characteristics of the individuals included per study are available **Supplementary Table 1**.

Ethics

Study participants in HUNT have given written consent for the use of their data for research. The Regional Ethics Committee (REC) for Medical and Health Research Ethics in Central

686 Norway have approved the study (REC reference number: 2018/1622). The UK Biobank
687 received written consent from all the participants. UK Biobank was approved by the National
688 Health Service (NHS) Research Ethics Service (reference number 11/NW/0382). The analyses
689 in MGI have been approved by the Institutional review Board of the University of Michigan
690 Medical School (IRB IDs HUM00071298, HUM00148297, HUM00099197, HUM00097962, and
691 HUM00106315). Study subjects in FinnGen provided informed consent for biobank research,
692 based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the
693 Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017),
694 were collected based on study-specific consents and later transferred to the Finnish biobanks
695 after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for
696 Welfare and Health. Recruitment protocols followed the biobank protocols approved by
697 Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa
698 (HUS) statement number for the FinnGen study is Nr HUS/990/2017. The FinnGen study is
699 approved by Finnish Institute for Health and Welfare (permit numbers:
700 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018,
701 THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and
702 THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers:
703 VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution
704 (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA
705 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA
706 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,
707 THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020,
708 THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021,
709 THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021,
710 THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics
711 Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20)
712 TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases
713 permission/extract from the meeting minutes on 4th July 2019. The Biobank Access Decisions
714 for FinnGen samples and data utilized in FinnGen Data Freeze 12 include: THL Biobank
715 BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7,
716 BB2019_8, BB2019_26, BB2020_1, BB2021_65, Finnish Red Cross Blood Service Biobank
717 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/430/2021 §28, §29,

HUS/150/2022 §12, §13, §14, §15, §16, §17, §18, §23, §58, §59, HUS/128/2023 §18, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB_2021-0140, BB_2021-0156 (August 26 2021, Feb 2 2022), BB_2021-0169, BB_2021-0179, BB_2021-0161, AB20-5926 and amendment #1 (April 23 2020) and it´s modifications (Sep 22 2021), BB_2022-0262, BB_2022-0256, Biobank Borealis of Northern Finland_2017_1013, 2021_5010, 2021_5010 Amendment, 2021_5018, 2021_5018 Amendment, 2021_5015, 2021_5015 Amendment, 2021_5015 Amendment_2, 2021_5023, 2021_5023 Amendment, 2021_5023 Amendment_2, 2021_5017, 2021_5017 Amendment, 2022_6001, 2022_6001 Amendment, 2022_6006 Amendment, 2022_6006 Amendment, 2022_6006 Amendment_2, BB22-0067, 2022_0262, 2022_0262 Amendment, Biobank of Eastern Finland 1186/2018 and amendment 22§/2020, 53§/2021, 13§/2022, 14§/2022, 15§/2022, 27§/2022, 28§/2022, 29§/2022, 33§/2022, 35§/2022, 36§/2022, 37§/2022, 39§/2022, 7§/2023, 32§/2023, 33§/2023, 34§/2023, 35§/2023, 36§/2023, 37§/2023, 38§/2023, 39§/2023, 40§/2023, 41§/2023, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), BB2021-0140 8§/2021, 9§/2021, §9/2022, §10/2022, §12/2022, 13§/2022, §20/2022, §21/2022, §22/2022, §23/2022, 28§/2022, 29§/2022, 30§/2022, 31§/2022, 32§/2022, 38§/2022, 40§/2022, 42§/2022, 1§/2023, Central Finland Biobank 1-2017, BB_2021-0161, BB_2021-0169, BB_2021-0179, BB_2021-0170, BB_2022-0256, BB_2022-0262, BB22-0067, Decision allowing to continue data processing until 31st Aug 2024 for projects: BB_2021-0179, BB22-0067,BB_2022-0262, BB_2021-0170, BB_2021-0164, BB_2021-0161, and BB_2021-0169, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC_2021_1001.

Data availability

The data are available in the supplementary and upon request. The summary statistics for the meta-analyses are available at NTNU Open Research Data (https://dataverse.no/dataverse/ntnu DOI: *will be added*) and in the GWAS catalog (accession number: *will be added*). The data used from the UK Biobank can be obtained by application (https://www.ukbiobank.ac.uk). The summary level data should be requested directly to FinnGen and MGI (for MGI, by emailing AIDHI-Data-Solutions@umich.edu). The summary

level data from NHS are available at https://www.ebi.ac.uk/gwas/efotraits/HP_0000020 (study accession numbers: GCST009926, GCST009927, GCST009928, GCST0010205). The eQTL data used are available at https://www.ebi.ac.uk/eqtl/ and https://www.gtexportal.org/home/downloads/adult-gtex/qtl (for the bladder only). The summary statistics used to perform the PheWas (biomarkers, continuous and phecode traits) are available at https://pan-dev.ukbb.broadinstitute.org/, we used the manifest and corresponding data from the 11 April 2022. The summary statistics used for the genetic correlation section are available in the Complex Traits Genetics Virtual Lab server (https://vl.genoma.io/).

Code availability

The following publicly available tools have been used in this project:

R v.4.2.3-4.5.2, FUMA v1.6.1-1.6.5 (https://fuma.ctglab.nl/), SAIGE version 1.03 for GWAS using HUNT data and version 0.35.8.3 for GWAS using UK Biobank data (https://saigegit.github.io/SAIGE-doc/), METAL (https://genome.sph.umich.edu/wiki/METAL_Documentation), UCSC LiftOver command line tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver), plink v2 (https://www.cog-genomics.org/plink/2.0/), Coloc (https://github.com/chr1swallace/coloc) as implemented following the tutorial eQTL Catalog resource tutorial (https://github.com/eQTL-Catalogue/eQTL-Catalogue-resources/blob/master/tutorials/API_v2/eQTL_API_tutorial.md), LDSC Score Regression (https://github.com/bulik/ldsc). The code we used will be made available on GitHub: *link*.

Acknowledgement

We want to thank the participants and staff of The Trøndelag Health Study (HUNT), the UK Biobank, FinnGen and MGI.

The HUNT study is a collaboration between HUNT Research Center (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology [NTNU]), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The genotyping in HUNT was financed by the National Institutes of Health; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research

and Innovation in Central Norway; and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU). Analyses were performed in digital laboratories at HUNT Cloud, Norwegian University of Science and Technology (NTNU) (Trondheim, Norway).

This research has been conducted using the UK Biobank Resource under Application Number 40135.

We want to acknowledge the participants and investigators of the FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb Inc. (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Johnson&Johnson Innovative Medicine Inc., Novartis AG, Boehringer Ingelheim International GmbH and Bayer AG. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure (https://www.bbmri-eric.eu/national-nodes/finland/). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

The authors acknowledge the Michigan Genomics Initiative participants, AI & Digital Health Innovation at the University of Michigan, and the University of Michigan Medical School Data

Office for Clinical and Translational Research for providing data storage, management, processing, and distribution services. The authors acknowledge the Michigan Genomics Initiative participants, AI & Digital Health Innovation at the University of Michigan, the University of Michigan Medical School Central Biorepository, and the University of Michigan Advanced Genomics Core for providing data and specimen storage, management, processing, and distribution services, and the Center for Statistical Genetics in the Department of Biostatistics at the School of Public Health for genotype data curation, imputation, and management in support of the research reported in this publication.

BMB is supported by grants from the Liaison Committee for Education, Research and Innovation in Central Norway and the Joint Research Committee between St. Olavs Hospital and the Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU).

BNW is supported from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101110878 and from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101016775. N.M.

WZ was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R01HG014518. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Pizzol D, Demurtas J, Celotto S, Maggi S, Smith L, Angiolelli G, et al. Urinary incontinence and quality of life: a systematic review and meta-analysis. Aging Clin Exp Res. 2021 Jan;33(1):25–35. doi:10.1007/s40520-020-01712-y PubMed PMID: 32964401; PubMed Central PMCID: PMC7897623.

2. Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillén U, et al. Epidemiology of Urinary Incontinence (UI) and other Lower Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse (POP) and Anal Incontinence (AI). In: Abrams P, Cardozo L, Khoury S, Wein AJ, editors. Incontinence. Paris: ICUD-EAU; 2013. p. 15–107.

3. Aoki Y, Brown HW, Brubaker L, Cornu JN, Daly JO, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primer. 2017 Jul 6;3(1):1–20. doi:10.1038/nrdp.2017.42

4. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of

the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. doi:10.1002/nau.10052

5. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. doi:10.1002/nau.20798

6. Falah-Hassani K, Reeves J, Shiri R, Hickling D, McLean L. The pathophysiology of stress urinary incontinence: a systematic review and meta-analysis. Int Urogynecology J. 2021;32(3):501–52. doi:10.1007/s00192-020-04622-9 PubMed PMID: 33416968; PubMed Central PMCID: PMC8053188.

7. Breinbjerg A, Jørgensen CS, Borg B, Rittig S, Kamperis K, Christensen JH. The genetics of incontinence: A scoping review. Clin Genet. 2023;104(1):22–62. doi:10.1111/cge.14331

8. Penney KL, Townsend MK, Turman C, Glass K, Staller K, Kraft P, et al. Genome-Wide Association Study for Urinary and Fecal Incontinence in Women. J Urol. 2019 Nov 15;203(5):978. doi:10.1097/JU.0000000000000655 PubMed PMID: 31729902.

9. Cartwright R, Franklin L, Tikkinen KAO, Kalliala I, Miotla P, Rechberger T, et al. Genome-Wide Association Study Identifies Two Novel Loci Associated with Female Stress and Urgency Urinary Incontinence. J Urol. 2021 Sep;206(3):679–87. doi:10.1097/JU.0000000000001822 PubMed PMID: 33904754.

10. Minassian VA, Ghandour R, Hao L, Gabriel I. Genome-Wide Associations with Urinary Incontinence in Women: Case-Control Study. Int Urogynecology J. 2025 Jul 24. doi:10.1007/s00192-025-06180-4 PubMed PMID: 40705065.

11. Funada S, Kawaguchi T, Terada N, Negoro H, Tabara Y, Kosugi S, et al. Cross-Sectional Epidemiological Analysis of the Nagahama Study for Correlates of Overactive Bladder: Genetic and Environmental Considerations. J Urol. 2018 Mar;199(3):774–8. doi:10.1016/j.juro.2017.09.146 PubMed PMID: 29066362.

12. Richter HE, Whitehead N, Arya L, Ridgeway B, Allen-Brady K, Norton P, et al. Genetic Contributions to Urgency Urinary Incontinence in Women. J Urol. 2015 Jun. Located at: Philadelphia, PA. doi:10.1016/j.juro.2014.12.023

13. Post WM, Widomska J, Oosterwijk E, De Witte W, Coenen MJH, Janssen DAW, et al. A Molecular Landscape of Stress Urinary Incontinence in Women Suggests an Important Role of Beta-Catenin Signaling in Disease Etiology. JU Open Plus. 2023 Apr;1(4):e00017. doi:10.1097/JU9.0000000000000019

14. Batmani S, Jalali R, Mohammadi M, Bokaee S. Prevalence and factors related to urinary incontinence in older adults women worldwide: a comprehensive systematic review and meta-analysis of observational studies. BMC Geriatr. 2021 Mar 29;21(1):212. doi:10.1186/s12877-021-02135-8 PubMed PMID: 33781236; PubMed Central PMCID: PMC8008630.

15. Olagundoye O, Odusanya B, Kung JY, Gibson W, Wagg A. A scoping review of risk factors for urinary incontinence in older men. BMC Geriatr. 2023 Sep 2;23(1):534. doi:10.1186/s12877-023-04249-7 PubMed PMID: 37660036; PubMed Central PMCID: PMC10474661.

16. Patel UJ, Godecker AL, Giles DL, Brown HW. Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data. Female Pelvic Med Reconstr Surg. 2022 Apr 1;28(4):181–7. doi:10.1097/SPV.0000000000001127 PubMed PMID: 35030139.

17. Liu W, Qian L. Risk factors for postpartum stress urinary incontinence: a prospective study. BMC Urol. 2024 Feb 16;24(1):42. doi:10.1186/s12894-024-01430-x

18. Cuéllar-Partida G, Lundberg M, Kho PF, D'Urso S, Gutiérrez-Mondragón LF, Ngo TT, et al. Complex-Traits Genetics Virtual Lab: A community-driven web platform for post-GWAS analyses [Internet]. bioRxiv; 2019 [cited 2025 Sep 5]. p. 518027. Available from: https://www.biorxiv.org/content/10.1101/518027v4 doi:10.1101/518027

19. Cartwright R, Kirby AC, Tikkinen KAO, Mangera A, Thiagamoorthy G, Rajan P, et al. Systematic review and metaanalysis of genetic association studies of urinary symptoms and prolapse in women. Am J Obstet Gynecol. 2015 Feb;212(2):199.e1-24. doi:10.1016/j.ajog.2014.08.005 PubMed PMID: 25111588; PubMed Central PMCID: PMC4342521.

20. Kattah NH, Kattah MG, Utz PJ. The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev. 2010 Jan;233(1):126–45. doi:10.1111/j.0105-2896.2009.00863.x PubMed PMID: 20192997; PubMed Central PMCID: PMC3074261.

21. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline Mutations in HOXB13 and Prostate-Cancer Risk. N Engl J Med. 2012 Jan 12;366(2):141–9. doi:10.1056/NEJMoa1110000

22. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 Jul;50(7):928–36. doi:10.1038/s41588-018-0142-8 PubMed PMID: 29892016; PubMed Central PMCID: PMC6568012.

23. Steiglitz BM, Keene DR, Greenspan DS. PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1. J Biol Chem. 2002 Dec 20;277(51):49820–30. doi:10.1074/jbc.M209891200 PubMed PMID: 12393877.

24. PB | Collagen formation [Internet]. [cited 2025 Sep 5]. Available from: https://reactome.org/PathwayBrowser/#/R-HSA-1474290

25. Weledji EP, Assob JC. The ubiquitous neural cell adhesion molecule (N-CAM). Ann Med Surg. 2014 Sep 1;3(3):77–81. doi:10.1016/j.amsu.2014.06.014

26. PB | ECM proteoglycans [Internet]. [cited 2025 Sep 5]. Available from: https://reactome.org/PathwayBrowser/#/R-HSA-1474244&SEL=R-HSA-3000178

27. Elkenani M, Barakat AZ, Held T, Rodrigues DM, Mobarak S, Swarnka S, et al. Heat shock protein A4 ablation leads to skeletal muscle myopathy associated with dysregulated autophagy and induced apoptosis. J Transl Med. 2022 May 14;20(1):229. doi:10.1186/s12967-022-03418-3 PubMed PMID: 35568953; PubMed Central PMCID: PMC9107738.

28. Kazi AA, Hong-Brown L, Lang SM, Lang CH. Deptor Knockdown Enhances mTOR Activity and Protein Synthesis in Myocytes and Ameliorates Disuse Muscle Atrophy. Mol Med. 2011;17(9–

10):925–36. doi:10.2119/molmed.2011.00070 PubMed PMID: 21607293; PubMed Central PMCID: PMC3188866.

29. Tasian G, Cunha G, Baskin L. Smooth Muscle Differentiation and Patterning in the Urinary Bladder. Differ Res Biol Divers. 2010;80(0):106–17. doi:10.1016/j.diff.2010.05.004 PubMed PMID: 20541860; PubMed Central PMCID: PMC3712869.

30. Kaczmarek A, Kaczmarek M, Ciałowicz M, Clemente FM, Wolański P, Badicu G, et al. The Role of Satellite Cells in Skeletal Muscle Regeneration—The Effect of Exercise and Age. Biology. 2021 Oct 18;10(10):1056. doi:10.3390/biology10101056 PubMed PMID: 34681155; PubMed Central PMCID: PMC8533525.

31. Ashton-Miller JA, Howard D, DeLancey JOL. The Functional Anatomy of the Female Pelvic Floor and Stress Continence Control System. Scand J Urol Nephrol Suppl. 2001;(207):1–125. doi:10.1080/003655901750174773 PubMed PMID: 11409608; PubMed Central PMCID: PMC1192576.

32. Brain Malformations with or Without Urinary Tract Defects - MalaCards [Internet]. [cited 2026 Feb 18]. Available from: https://www.malacards.org/card/brain_malformations_with_or_without_urinary_tract_defects#RelatedDisorders

33. Bastide L, Herbaut AG. Cerebellum and micturition: what do we know? A systematic review. Cerebellum Ataxias. 2020 Jul 18;7(1):9. doi:10.1186/s40673-020-00119-9

34. Seseke S, Baudewig J, Kallenberg K, Ringert RH, Seseke F, Dechent P. Gender differences in voluntary micturition control — An fMRI study. NeuroImage. 2008 Nov 1;43(2):183–91. doi:10.1016/j.neuroimage.2008.07.044

35. Matsuo T, Kakita S, Honda H, Mori S, Araki K, Mitsunari K, et al. Relationship Between Tooth Loss Due to Chronic Periodontitis and Lower Urinary Tract Symptoms. Medicina (Mex). 2024 Nov 7;60(11):1829. doi:10.3390/medicina60111829 PubMed PMID: 39597014; PubMed Central PMCID: PMC11596325.

36. Lee AH, Hirayama F. Is Alcohol Consumption Associated with Male Urinary Incontinence? Low Urin Tract Symptoms. 2011 Apr;3(1):19–24. doi:10.1111/j.1757-5672.2010.00078.x PubMed PMID: 26676347.

37. Krokstad S, Langhammer A, Hveem K, Holmen TL, Midthjell K, Stene TR, et al. Cohort Profile: the HUNT Study, Norway. Int J Epidemiol. 2013 Aug;42(4):968–77. doi:10.1093/ije/dys095 PubMed PMID: 22879362.

38. Åsvold BO, Langhammer A, Rehn TA, Kjelvik G, Grøntvedt TV, Sørgjerd EP, et al. Cohort Profile Update: The HUNT Study, Norway. Int J Epidemiol. 2023 Feb 8;52(1):e80–91. doi:10.1093/ije/dyac095 PubMed PMID: 35578897; PubMed Central PMCID: PMC9908054.

39. Næss M, Kvaløy K, Sørgjerd EP, Sætermo KS, Norøy L, Røstad AH, et al. Data Resource Profile: The HUNT Biobank. Int J Epidemiol. 2024 Apr 11;53(3):dyae073. doi:10.1093/ije/dyae073

40. Brumpton BM, Graham S, Surakka I, Skogholt AH, Løset M, Fritsche LG, et al. The HUNT study: A population-based cohort for genetic research. Cell Genomics. 2022 Oct 12;2(10):100193. doi:10.1016/j.xgen.2022.100193 PubMed PMID: 36777998; PubMed Central PMCID: PMC9903730.

41. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9. doi:10.1038/s41586-018-0579-z

42. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023 Jan;613(7944):508–18. doi:10.1038/s41586-022-05473-8

43. Pärn K, Isokallio MA, Fontarnau JN, Palotie A, Ripatti S, Palta P. Genotype imputation workflow v3.0 [Internet]. 2018 May 10 [cited 2024 Dec 30]. Available from: https://www.protocols.io/view/genotype-imputation-workflow-v3-0-nmndc5e

44. Zawistowski M, Fritsche LG, Pandit A, Vanderwerff B, Patil S, Schmidt EM, et al. The Michigan Genomics Initiative: A biobank linking genotypes and electronic clinical records in Michigan Medicine patients. Cell Genomics. 2023 Jan 31;3(2):100257. doi:10.1016/j.xgen.2023.100257 PubMed PMID: 36819667; PubMed Central PMCID: PMC9932985.

45. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer. 2005 May;5(5):388–96. doi:10.1038/nrc1608

46. Lindström S, Loomis S, Turman C, Huang H, Huang J, Aschard H, et al. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS ONE. 2017 Mar 16;12(3):e0173997. doi:10.1371/journal.pone.0173997 PubMed PMID: 28301549; PubMed Central PMCID: PMC5354293.

47. Zhou W, Zhao Z, Nielsen JB, Fritsche LG, LeFaive J, Gagliano Taliun SA, et al. Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. Nat Genet. 2020 Jun;52(6):634–9. doi:10.1038/s41588-020-0621-6

48. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015 Mar;47(3):291–5. doi:10.1038/ng.3211

49. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of genetic correlations across human diseases and traits. Nat Genet. 2015 Nov;47(11):1236–41. doi:10.1038/ng.3406

50. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010 Sep 1;26(17):2190–1. doi:10.1093/bioinformatics/btq340

51. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, et al. The UCSC Genome Browser Database: update 2006. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590–8. doi:10.1093/nar/gkj144 PubMed PMID: 16381938; PubMed Central PMCID: PMC1347506.

52. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017 Nov 28;8(1):1826. doi:10.1038/s41467-017-01261-5 PubMed PMID: 29184056; PubMed Central PMCID: PMC5705698.

53. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. Nature. 2015 Oct;526(7571):68–74. doi:10.1038/nature15393

54. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2010 Sep 15;26(18):2336–7. doi:10.1093/bioinformatics/btq419

55. De Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. Tang H, editor. PLOS Comput Biol. 2015 Apr 17;11(4):e1004219. doi:10.1371/journal.pcbi.1004219

56. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014 May;10(5):e1004383. doi:10.1371/journal.pgen.1004383 PubMed PMID: 24830394; PubMed Central PMCID: PMC4022491.

57. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, et al. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat Genet. 2021 Sep;53(9):1290–9. doi:10.1038/s41588-021-00924-w

58. Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLOS Genet. 2020 Apr 20;16(4):e1008720. doi:10.1371/journal.pgen.1008720

59. Bastarache L. Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS. Annu Rev Biomed Data Sci. 2021 Jul 20;4:1–19. doi:10.1146/annurev-biodatasci-122320-112352 PubMed PMID: 34465180; PubMed Central PMCID: PMC9307256.

60. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019 Apr 16;10(1):1776. doi:10.1038/s41467-019-09718-5

61. Mathieson I, Day FR, Barban N, Tropf FC, Brazel DM, van Heemst D, et al. Genome-wide analysis identifies genetic effects on reproductive success and ongoing natural selection at the FADS locus. Nat Hum Behav. 2023 May;7(5):790–801. doi:10.1038/s41562-023-01528-6

62. Pujol-Gualdo N, Läll K, Lepamets M, Rossi HR, Arffman RK, Piltonen TT, et al. Advancing our understanding of genetic risk factors and potential personalized strategies for pelvic organ prolapse. Nat Commun. 2022 Jun 23;13(1):3584. doi:10.1038/s41467-022-31188-5

63. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in ∼700000 individuals of European ancestry. Hum Mol Genet. 2018 Oct 15;27(20):3641–9. doi:10.1093/hmg/ddy271

64. Gudmundsson J, Sigurdsson JK, Stefansdottir L, Agnarsson BA, Isaksson HJ, Stefansson OA, et al. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat Commun. 2018 Nov 8;9(1):4568. doi:10.1038/s41467-018-06920-9

65. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates. Eur J Epidemiol. 2018;33(10):947–52. doi:10.1007/s10654-018-0424-6 PubMed PMID: 30039250; PubMed Central PMCID: PMC6153517.



Figure 1: Study design and key findings. Flowchart summarizing the analytical workflow and main results. AUI; Any type of urinary incontinence. SUI; stress urinary incontinence. UUI; urge urinary incontinence. MUI; mixed urinary incontinence. ICD; International Classification of Diseases. srq; self-reported questionnaire. HUNT; Trøndelag Health Study. MGI; Michigan Genomics Initiative. MR; Mendelian Randomization. PRS; polygenic risk scores. PheWAS; phenome-wide association studies.

Table 1. Summary of the top lead variants identified in the meta-analyses of UI phenotype.

We present results for males and females for sake of clarity, results for sex-combined analyses are available in Supplementary Table 3.

The loci are presented for each phenotypes: any type of urinary incontinence (AUI), stress urinary incontinence (SUI), urge urinary incontinence (UUI) and mixed urinary incontinence (MUI) for surveys and ICD phenotypes definitions (International Classification of Diseases). The variants are given with position in GRCH37. Allele frequency (AF) and effects size with standard error (SE) are given for the effect allele. Heterogeneity estimates are presented with the heterogeneity I squared (HetISq)and the heterogeneity p-value (HetPVal). N=sample size; Studies: F=FinnGen, H=HUNT, M=MGI, N=NHS, U=UK Biobank. Asterisks represents loci identified manually, filtered out by FUMA with the use of the 1000G European reference panel. For those, the Position SNP and the nearest gene were searched in VEP.

Definition	Sex	Novelty	Trait	rsID	Chrom:Pos	EA	AF	Effect	SE	P-value	N	Studies	Nearest gene
ICD	Females	Novel	AUI	rs11807521	1:61844272	a	0,1041	0,0839	0,0125	1,69E-11	572696	H,U,F,M	*NFIA*
ICD	Females	Novel	AUI	rs10200533	2:144183002	a	0,507	-0,0485	0,0076	1,57E-10	572696	H,U,F,M	*ARHGAP15:AC096558.1:RP11-570L15.2*
ICD	Females	Novel	AUI	rs34125679	2:9304212	a	0,3105	0,0484	0,0088	3,21E-08	526672	U,F,M	*RP11-734K21.4*
ICD	Females	Novel	AUI	rs533589387	2:205377594	t	0,0001	4,5619	0,8052	1,47E-08	220559	U	*AC016903.2*
ICD	Females	Novel	AUI	rs35783198	3:142607767	t	0,1725	-0,064	0,0102	2,86E-10	572696	H,U,F,M	*PCOLCE2*
ICD	Females	Novel	AUI	rs191824624*	4:105628607	t	0,0002	3,7488	0,6744	2,72E-08	220559	U	*RP11-556I14.2*
ICD	Females	Novel	AUI	rs6817714	4:126914437	a	0,1953	0,0579	0,0095	1,10E-09	572696	H,U,F,M	*RP11-318I4.1*

ICD	Females	Novel	AUI	rs251387	5:127547180	t	0,2367	-0,0512	0,009	1,17E-08	572696	H,U,F,M	*SLC12A2*
ICD	Females	Novel	AUI	rs4705880	5:132433618	a	0,2688	-0,0531	0,0093	1,36E-08	540027	H,U,F	*HSPA4*
ICD	Females	Novel	AUI	rs2814985	6:34548296	t	0,17	0,0592	0,0102	6,35E-09	572696	H,U,F,M	*RP3-391O22.3*
ICD	Females	Novel	AUI	rs9295224	6:163948935	c	0,2974	0,0455	0,0083	4,68E-08	572696	H,U,F,M	*QKI*
ICD	Females	Novel	AUI	rs11770163	7:116417848	c	0,3443	0,049	0,008	7,50E-10	572696	H,U,F,M	*MET*
ICD	Females	Novel	AUI	rs201423153	7:27285729	t	0,007	0,2923	0,0454	1,25E-10	572696	H,U,F,M	*EVX1-AS:EVX1*
ICD	Females	Novel	AUI	rs13257316	8:120903734	a	0,5245	0,0426	0,0076	2,01E-08	572696	H,U,F,M	*DEPTOR*
ICD	Females	Novel	AUI	rs11188337	10:97266574	a	0,2088	-0,0585	0,0095	6,39E-10	572696	H,U,F,M	*SORBS1*
ICD	Females	Novel	AUI	rs1155027	11:112815088	t	0,3489	-0,049	0,008	7,82E-10	572696	H,U,F,M	*RP11-629G13.1*
ICD	Females	Novel	AUI	rs2625291	11:19913145	a	0,1224	0,0775	0,0124	4,17E-10	572696	H,U,F,M	*NAV2*
ICD	Females	Novel	AUI	rs4584608	11:74325648	a	0,2326	0,0759	0,009	4,27E-17	572696	H,U,F,M	*POLD3*
ICD	Females	Novel	AUI	rs10774740	12:114666202	t	0,4089	-0,073	0,0078	5,25E-21	572696	H,U,F,M	*RP11-139B1.1*

ICD	Females	Novel	AUI	rs2806936	13:53749752	t	0,4425	0,0434	0,0076	1,12E-08	572696	H,U,F,M	*LINC01065*
ICD	Females	Novel	AUI	rs55908306	15:96692572	a	0,1821	0,0661	0,01	3,02E-11	572696	H,U,F,M	*NR2F2-AS1*
ICD	Females	Novel	AUI	rs11658346	17:12321794	t	0,3216	-0,0666	0,0085	4,33E-15	572696	H,U,F,M	*LINC00670*
ICD	Females	Novel	AUI	rs78261338	17:56396836	a	0,0132	0,2055	0,0365	1,88E-08	572696	H,U,F,M	*BZRAP1*
ICD	Females	Novel	SUI	rs3820282	1:22468215	t	0,158	0,0761	0,0135	1,74E-08	553275	H,U,F,M	*WNT4*
ICD	Females	Novel	SUI	rs189905208	2:5789613	a	0,9671	-0,1587	0,0288	3,49E-08	553275	H,U,F,M	*AC107057.2:AC108025.2*
ICD	Females	Novel	SUI	rs4662329	2:144164134	a	0,5557	-0,0625	0,01	3,54E-10	553275	H,U,F,M	*ARHGAP15:AC096558.1:RP11-570L15.2*
ICD	Females	Novel	SUI	rs7255	2:20878820	t	0,4763	0,057	0,01	1,15E-08	553275	H,U,F,M	*AC012065.7*
ICD	Females	Novel	SUI	rs7600398	2:100460695	a	0,7109	0,0721	0,0121	2,43E-09	508549	U,F,M	*AFF3*
ICD	Females	Novel	SUI	rs78579538	3:142615990	a	0,8272	0,1149	0,0133	5,03E-18	553275	H,U,F,M	*PCOLCE2*
ICD	Females	Novel	SUI	rs12647708	4:126921277	t	0,8029	-0,0932	0,0123	4,01E-14	553275	H,U,F,M	*RP11-318I4.1*
ICD	Females	Novel	SUI	rs138541831	4:70529893	t	0,0597	0,1152	0,0206	2,29E-08	553275	H,U,F,M	*UGT2A1*

ICD	Females	Novel	SUI	rs6856764	4:76278309	a	0,2945	-0,0636	0,0109	5,72E-09	553275	H,U,F,M	*RP11-542G1.1: RP11-542G1.2*
ICD	Females	Novel	SUI	rs251387	5:127547180	t	0,2367	-0,0816	0,0118	3,88E-12	553275	H,U,F,M	*SLC12A2*
ICD	Females	Novel	SUI	rs4895902	6:131329259	a	0,7735	0,0659	0,0121	4,48E-08	553275	H,U,F,M	*EPB41L2*
ICD	Females	Novel	SUI	rs41741	7:116438511	t	0,6563	-0,0802	0,0104	1,08E-14	553275	H,U,F,M	*MET*
ICD	Females	Novel	SUI	rs570853750	7:26951709	a	0,0068	0,355	0,06	3,23E-09	553275	H,U,F,M	*SKAP2*
ICD	Females	Novel	SUI	rs10505131	8:110667078	t	0,7976	-0,0693	0,0122	1,31E-08	553275	H,U,F,M	*SYBU*
ICD	Females	Novel	SUI	rs1409714	10:97263791	a	0,2092	-0,0851	0,0124	6,09E-12	553275	H,U,F,M	*SORBS1*
ICD	Females	Novel	SUI	rs10765541	11:91941510	t	0,4386	0,0561	0,01	2,28E-08	553275	H,U,F,M	*RPL7AP57*
ICD	Females	Novel	SUI	rs10891477	11:112813307	a	0,3436	-0,0821	0,0105	4,89E-15	553275	H,U,F,M	*RP11-629G13.1*
ICD	Females	Novel	SUI	rs2067666	11:32498355	t	0,8543	-0,1	0,0139	7,11E-13	553275	H,U,F,M	*WT1-AS*
ICD	Females	Novel	SUI	rs2625291	11:19913145	a	0,1221	0,1137	0,0162	2,54E-12	553275	H,U,F,M	*NAV2*
ICD	Females	Novel	SUI	rs72979233	11:74355523	a	0,7649	0,0901	0,0118	2,33E-14	553275	H,U,F,M	*POLD3*
ICD	Females	Novel	SUI	rs10774740	12:114666202	t	0,4076	-0,0901	0,0102	7,71E-1	553275	H,U,F,M	*RP11-139B1.1*

										9			
ICD	Females	Novel	SUI	rs11658346	17:12321794	t	0,3207	-0,0881	0,0111	2,25E-15	553275	H,U,F,M	*LINC00670*
ICD	Females	Novel	SUI	rs2229989	17:70118935	t	0,2489	0,0637	0,0116	4,02E-08	553275	H,U,F,M	*SOX9-AS1:SOX9*
ICD	Females	Novel	SUI	rs7291533	22:19737610	t	0,6231	0,0628	0,0105	2,21E-09	553275	H,U,F,M	*TBX1*
ICD	Females	Novel	UUI	rs12064509	1:61845270	c	0,8967	-0,0993	0,0172	7,51E-09	550826	H,U,F,M	*NFIA*
ICD	Females	Novel	UUI	rs10774740	12:114666202	t	0,4096	-0,0699	0,0107	5,28E-11	550826	H,U,F,M	*RP11-139B1.1*
ICD	Females	Novel	UUI	rs77292069	20:56366577	a	0,0012	1,3097	0,2325	1,77E-08	286515	H,U,M	*PMEPA1*
ICD	Females	Novel	MUI	rs55692570	3:142631347	t	0,1719	-0,1214	0,0213	1,22E-08	538329	H,U,F,M	*RP11-372E1.4*
ICD	Females	Novel	MUI	rs10774740	12:114666202	t	0,4044	-0,0959	0,0163	3,90E-09	538329	H,U,F,M	*RP11-139B1.1*
ICD	Females	Novel	MUI	rs9468	17:44101563	t	0,8145	-0,1156	0,0212	4,92E-08	538329	H,U,F,M	*MAPT*
ICD	Males	Novel	AUI	rs138213197	17:46805705	t	0,0049	0,5817	0,0991	4,42E-09	472740	H,U,F,M	*HOXB13*
ICD	Males	Novel	SUI	rs77541621	8:128077146	a	0,027	0,5835	0,0833	2,48E-12	459515	H,U,F,M	*PCAT2*
ICD	Males	Novel	SUI	rs10993994*	10:51549496	a	0,3786	0,1917	0,035	4,15E-08	240257	F,M	*MSMB*

ICD	Males	Novel	SUI	rs538936557	11:55455982	a	0,0564	1,2006	0,218	3,65E-08	179109	U	*RP11-674C21.9*
ICD	Males	Novel	SUI	rs138213197	17:46805705	t	0,006	1,2284	0,1787	6,32E-12	459515	H,F,M	*HOXB13*
ICD	Males	Novel	SUI	rs4430796	17:36098040	a	0,5533	0,188	0,0306	8,50E-10	459515	H,U,F,M	*HNF1B*
ICD	Males	Novel	UUI	rs13266066	8:141700117	t	0,4771	0,0815	0,0146	2,45E-08	467379	H,U,F,M	*PTK2*
ICD	Males	Novel	UUI	rs201998020*	9:132394938	a	0,0003	5,1863	0,9441	3,94E-08	225828	H,U	*ASB6, NTMT1*
ICD	Males	Novel	MUI	rs765377367*	8:115038254	a	0,0007	116,031	18,7513	6,10E-10	40476	H	.
Surveys	Females	Novel	AUI	rs7600346	2:153130367	t	0,2122	0,0936	0,0163	9,09E-09	56955	N,H	*Y_RNA*
Surveys	Females	Novel	AUI	rs78579538	3:142615990	a	0,8436	0,1062	0,0184	7,68E-09	56955	N,H	*PCOLCE2*
Surveys	Females	Novel	AUI	rs554550612	12:23441817	t	0,0028	0,8146	0,1485	4,13E-08	46024	H	*RP11-153K16.2*
Surveys	Females	Known [Penney et al.]	SUI	rs2270016	2:74686329	t	0,1616	0,1329	0,0206	1,09E-10	51346	N,H	*INO80B:WBP1*
Surveys	Females	Known [Cartwright et al.]	SUI	rs1448813496*	2:119807995	a	0,0005	2,6354	0,4623	1,20E-08	44726	H	.

Surveys	Females	Novel	SUI	rs78579538	3:142615990	a	0,8429	0,1211	0,0208	5,54E-09	51346	N,H	*PCOLCE2*
Surveys	Females	Novel	UUI	rs554550612	12:23441817	t	0,0027	0,9891	0,1736	1,22E-08	43825	H	*RP11-153K16.2*
Surveys	Females	Novel	MUI	rs554550612	12:23441817	t	0,0026	1,2101	0,2011	1,76E-09	42616	H	*RP11-153K16.2*



Figure 2: Summary of the associations for the UI phenotypes for the females (ICD based definitions). Venn diagram illustrating the small amount of genetic overlap between the main subtypes (SUI in orange, UUI in pink and MUI in yellow). The locus close to RP11-139B1.1 was shared between all the UI phenotypes. AUI; any type of urinary incontinence. SUI; stress urinary incontinence. UUI; urge urinary incontinence. MUI; mixed urinary incontinence. ICD; International Classification of Diseases.